Serina Therapeutics Inc
SER
查看详细走势图
1.910USD
-0.700-26.82%
交易中 （美东）报价延迟15分钟
1.95M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-26.82%
5天
-24.80%
1月
+6.11%
6月
-60.94%
今年开始到现在
-0.16%
1年
-63.89%
查看详细走势图
TradingKey Serina Therapeutics Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Serina Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名150/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价13.00。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Serina Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Serina Therapeutics Inc亮点
亮点风险
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
业绩增长期
公司处于发展阶段，最新年度总收入130.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入130.00K美元
估值合理
公司最新PE估值-1.19，处于3年历史合理位
机构减仓
最新机构持股455.00K股，环比减少7.87%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值180.01K
分析师目标
根据
2
位分析师
买入
评级
13.000
目标均价
+398.08%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Serina Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Serina Therapeutics Inc简介
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
公司代码SER
公司Serina Therapeutics Inc
CEOLedger (Steven)
网址https://serinatherapeutics.com/
相关品种
